COVID-19: Top science stories of the week, from old antibodies to new vaccines

A computer image created by Nexu Science Communication together with Trinity College in Dublin, shows a model structurally representative of a betacoronavirus which is the type of virus linked to COVID-19, better known as the coronavirus linked to the Wuhan outbreak, shared with Reuters on February 18, 2020.

A computer image showing a model of the coronavirus that causes COVID-19. Image: NEXU Science Communication/via REUTERS

Alice Hazelton
Programme Lead, Science and Society, World Economic Forum Geneva
Greta Keenan
Lead, Strategic Impact and Communications, World Economic Forum Geneva
Sam Leakey
Programme Specialist, Science and Society, World Economic Forum Geneva
Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
  • Signs of at least temporary immunity after COVID-19 infection.
  • 2003 SARS outbreak antibodies also help to block the virus that causes COVID-19.
  • Preliminary vaccine trial results are out, but there remains a long way to go.

Evidence builds for natural immunity after infection

It is still not clear whether people infected with coronavirus are immune to the virus after they recover. It’s a key scientific question that needs to be addressed, especially as many health policies around the globe have been based on the assumption that populations will develop “herd immunity” over time.

New research from the Korean Centres for Disease Control and Prevention this week suggests that people who are re-infected with coronavirus are not infectious the second time around, and are - at least temporarily - immune.

Researchers tried to isolate infectious coronaviruses from samples taken from 108 people who retested positive after having been discharged from isolation. All of those samples tested negative. When the scientists examined 23 of those patients for antibodies against the coronavirus, almost all had neutralizing antibodies that prevent the virus getting into cells.

The team also tracked down 790 people who had come into contact with 285 people who retested positive. Of those contacts, 27 tested positive for the coronavirus, but none of these new cases appeared to originate from the reinfected patients, suggesting that those patients are likely not contagious.

SARS antibody also blocks new coronavirus

Researchers at the University of Washington in Seattle have found that an antibody from the blood of a SARS-survivor could help fight COVID-19.

Like the current pandemic, the 2003 SARS outbreak was caused by a coronavirus. The peer-reviewed study indicates that although the two viruses are distinct, the newly identified antibody (which they’ve named S309) can recognise and block both.

Antibodies block the virus by attaching to a ‘spike’ protein on the surface of the virus, preventing it from entering human cells. The researchers’ analysis shows that S309 binds to a different location than other known coronavirus antibodies. By combining S309 with other antibodies the researchers demonstrated that the antibody “cocktails" were more effective in blocking the virus than any of the antibodies alone. The researchers stated this offers some hope that S309 could help curtail the COVID-19 pandemic and also pave the way to better preparedness for future coronavirus outbreaks.

Have you read?

First human trial vaccine results

Eight volunteers have produced an antibody response to Moderna’s RNA vaccine as part of a first-stage trial of 45 people run by the National Institutes of Allergy and Infectious Diseases in the United States.

The results offer a glimmer of hope in getting closer to finding a vaccine that will end the COVID-19 pandemic, but experts caution that the results should be "taken with a grain of salt": only eight people produced an antibody response, there is no way of contextualising the findings and no way of telling how durable the response will be.

Time will tell how the vaccine fares, with Moderna intending to start the next stage of human trials involving 600 people shortly, and a much bigger trial involving thousands in July. The Moderna RNA vaccine is just one of 115 vaccine candidates registered with the World Health Organization (WHO) but the first to go to human trials. Stay tuned...

A graphic showing the timeline of accelerated vaccine production needed for COVID-19 which takes 12 to 18 months and costs at least 3 billion US dollars.
The theoretical timeline to which scientists are the world are working to produce a COVID-19 vaccine. Image: Wellcome Trust
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Sign in
  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum